Methandrostenolone

Summary

Methandrostenolone (CHEMBL1418176) is an approved small molecule (ATC D11AE01).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D11AE01 (+1 more)
• Chemistry: 300.4 Da · C20H28O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1418176
Name	Methandrostenolone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6300
ATC	D11AE01, A14AA03
Molecular formula	C20H28O2
Molecular weight	300.4
InChIKey	XWALNWXLMVGSFR-HLXURNFRSA-N

SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CCC4=CC(=O)C=C[C@]34C

IUPAC name: (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one

Also known as: Dianabol, Metandienona, Metandienone, Methandienone, Methandrostenolone, Nerobol, NSC-42722, Perbolin, SID29215353, SID144205200, METHANDIENONE, METHANDROL

Patent coverage: 892 distinct patent families (2,769 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Microtubule-associated protein tau, Prelamin-A/C.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	6.5	Potency	316.2	nM	CHEMBL_ACT_3663595
MAPT	6	Potency	1000	nM	CHEMBL_ACT_4527484
MAPT	5.4	Potency	3981	nM	CHEMBL_ACT_4066003

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).